EXPLORE!

Risankizumab enhances remission rates in moderate to severe refractory Crohns disease

  1119 Views

#Allergy and Immunology  #Gastroenterology 

eMediNexus    04 August 2018

Extended treatment with 600 mg intravenous risankizumab in patients with moderate to severe, treatment-refractory Crohns disease who were not in deep remission at week 12, increased clinical response and remission rates at week 26, as per a study published in the Lancet Gastroenterology and Hepatology.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.